Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab or Nivolumab/Ipilimumab in Progressive/Recurrent Meningioma
NCT02648997Phase 2Active, not recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Mar 2016
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab, ipilimumab in meningioma, sponsored by Dana-Farber Cancer Institute. Started Mar 2016; status: active, not recruiting.
02
Drugs
nivolumabipilimumab
03
Conditions
meningioma
Beyond the preview
Go deeper on NCT02648997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02648997.